[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"heart-failure-with-mid-range-ejection-fraction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:heart-failure-with-mid-range-ejection-fraction":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,57,91,127,155],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100444229","assessment-of-ccm-in-hf-with-higher-ejection-fraction-100444229",false,"NCT05064709","Assessment of CCM in HF With Higher Ejection Fraction","Assessment of Implantable CCM in the Heart Failure Group With Higher Ejection Fraction","AIM HIGHer","Inclusion Criteria:\n\n1. Signed and dated informed consent form;\n2. Male or non-pregnant female, 18 years or older;\n3. Diagnosed with symptomatic heart failure;\n4. LVEF ≥40 and ≤70% (as assessed by site echo);\n5. A. Heart failure hospitalization within 12 months prior to study consent OR an urgent heart failure visit requiring IV therapy within 6 months prior to study consent OR B. If there is no heart failure hospitalization within 12 months prior to study consent OR an urgent heart failure visit requiring IV therapy within 6 months prior to study consent, an elevated BMI-adjusted natriuretic peptide value must be achieved (Refer to Table 1 in Section 9.2.6)\n6. Subjects must meet one of the following conditions:\n\n   * Have stable, scheduled oral loop diuretic treatment (not just PRN) for a minimum of 30 days before providing study consent unless there is a documented allergy or intolerance.\n   * Eligibility for enrollment is maintained for patients on an SGLT2 inhibitor without prescribed concurrent standing loop diuretic therapy if investigators provide instructions for a flexible PRN diuretic regimen (deemed appropriate by the clinician in response to symptoms or weight gain) Note: Stable is defined as no more than a 100% increase or 50% decrease in dose within the last 30 days. A one-time hold of diuretic dosing for 24 hours during the 30-day period is allowed and not an exclusionary event.\n\nExclusion Criteria:\n\n1. Resting ventricular rate \\\u003C50 or \\>110 bpm;\n2. Resting systolic blood pressure \\\u003C100 or ≥160 mmHg;\n3. BMI greater than 46\n4. Any severe valvular stenotic disease or any severe valvular regurgitation;\n5. Mechanical tricuspid valve;\n6. Complex congenital heart disease;\n7. Exercise tolerance limited by a condition other than heart failure that, in the opinion of the investigator, contributes significantly to the primary symptoms of shortness of breath and\u002For exercise intolerance;\n8. Unable to walk at least 100 meters or walks more than 450 meters during a 6MWT;\n9. A KCCQ CCS score higher than 85;\n10. Hypertrophic, infiltrative\u002Frestrictive or inflammatory cardiomyopathy;\n11. Unstable angina pectoris within 30 days prior to study consent;\n12. Acute, decompensated heart failure requiring IV therapy or ultrafiltration within 30 days prior to consent, in the hospital or an outpatient setting;\n13. Receiving cardiac resynchronization therapy (CRT); NOTE: Subjects with active\u002Fongoing cardiac resynchronization therapy (CRT) implanted more than one year ago are eligible for inclusion if they are currently classified as NYHA class III or higher.\n14. Scheduled for a cardiac surgery or a percutaneous cardiac intervention (PCI) or have undergone cardiac surgery within 90 days or a PCI procedure within 30 days prior to study consent;\n15. Myocardial infarction within 90 days prior to study consent;\n16. Prior heart transplant or ventricular assist device;\n17. Planning to become pregnant during the study;\n18. Dialysis (permanent) or GFR \\\u003C15 ml\u002Fmin\u002F1.73m2;\n19. Participating in another investigational drug or device study that may interfere with the interpretation of study data;\n20. Currently undergoing active chemotherapeutic and\u002For radiation treatment for cancer or has a history of chemotherapy during the 2-year period prior to study consent;\n21. Expected lifespan of less than 18 months from time of study consent;\n22. Unable to follow through study protocol for any reasons in the investigator's judgement.","ALL","18 Years",{"count":20,"type":21},1500,"ESTIMATED","INTERVENTIONAL",[24],"NA","The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.",[27,28,29,30,31],"Heart Failure","Heart Failure With Preserved Ejection Fraction","Heart Failure With Mid Range Ejection Fraction","Heart Failure With Moderately Reduced Ejection Fraction","Diastolic Heart Failure",[33,34,35,36,37,38,39,40,41,42,43],"HFpEF","Heart failure","CCM","CCM therapy","cardiac contractility modulation","symptomatic heart failure","left ventricular ejection fraction","LVEF","Optimizer","Optimizer Smart Mini","Quality of Life","RECRUITING","2026-06-24",{"date":47,"type":48},"2026-06-26","ACTUAL",{"date":50,"type":48},"2022-02-03",{"date":52,"type":21},"2029-02-01",{"name":54,"class":55},"Impulse Dynamics","INDUSTRY",105,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":22,"phases":68,"briefSummary":69,"conditions":70,"keywords":76,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":4},"100609422","a-randomized-placebo-procedure-controlled-trial-of-the-enhancor-system-pulmonary-artery-denervation-to-evaluate-safety-and-efficacy-in-patients-with-combined-pre--and-post-capillary-pulmonary-hypertension-associated-with-left-heart-disease-100609422","NCT07214376","A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease","A Randomized Placebo-procedure Controlled Trial of the Multi-Pole Pulmonary Artery Radiofrequency Ablation Enhancor System PULmonary Artery Denervation Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease","The PULSE-LHD","Inclusion Criteria:\n\n1. Subject is ≥18 and ≤85 years of age\n2. Subject is diagnosed with chronic HF due to left-sided heart disease for at least 6 months prior to screening (regardless of LVEF), and remains symptomatic despite maximally tolerated class I GDMT for left heart failure and CRT as appropriate per US or EU guidelines according to region of enrollment\n3. Subject is clinically stable, defined as:\n\n   * No hospitalizations for heart failure for at least 1 month; no major changes in societal guideline-recommended class I oral GDMT for left heart failure for at least 1 month; no CRT or ICD implant in the prior 3 months; and no anticipated major changes in any HF-GDMT (other than possibly diuretic dose) or planned cardiac rhythm management device implantation after the procedure\n   * SBP is ≥90 and ≤160 mmHg and resting HR is ≥50 and ≤100 bpm (≤110 bpm for atrial fibrillation)\n4. PASP (RVSP) is ≥30 mmHg on the baseline TTE.\n5. Subject has New York Heart Association (NYHA) class II, III or IVa symptoms (IVa is defined as symptoms with minimal exertion or at rest, but the patient is able to ambulate and does not require continuous intravenous medications).\n6. Subject has 6MWD at baseline ranging from 100 to 450 m limited by dyspnea or fatigue and not orthopedic or other non-HF-related issues\n7. Subject has NT-proBNP ≥600 pg\u002FmL for patients with LVEF ≤40% or ≥200 pg\u002FmL for patients with LVEF \\>40% at the time of screening (a central lab will be made available for sites that cannot measure NT-proBNP)\n8. Subject is able and willing to follow all aspects of the research protocol including medication compliance and follow-up visits and testing.\n9. Subject or the subject's legally designated representative signs an IRB\u002FEC approved informed consent form prior to study participation.\n\nExclusion Criteria:\n\n1. Subject has a life expectancy of less than 1 year due to non-cardiovascular causes.\n2. Subject has known hypertrophic cardiomyopathy with either left ventricular (LV) outflow tract obstruction or systolic anterior motion (SAM) of the anterior leaflet of the mitral valve; pericardial disease; or infiltrative or active inflammatory myocardial disease, including known amyloidosis\n3. Subject has severe stenosis or regurgitation of any heart valve, moderate or severe stenosis of the aortic valve, or any degree of stenosis of the pulmonic valve\n4. Subject has symptomatic carotid stenosis, or transient ischemic attack (TIA) or stroke in the prior 30 days or any prior stroke with a permanent residual deficit with modified Rankin Scale (mRS) score ≥4\n5. Subject has any prior intracranial hemorrhage with or without a residual deficit, or any known intracranial pathology pre-disposing to bleeding (e.g. mass, AV fistula, aneurysm, etc.)\n6. Subjects with a known bleeding diathesis or who will refuse blood transfusions\n7. Subjects allergic to heparin (including heparin induced thrombocytopenia), unless bivalirudin or argatroban can be used for procedural anticoagulation\n8. Subjects with life threatening allergy to contrast dye that cannot be adequately pre-medicated, or any prior contrast-related anaphylaxis\n9. Subject has congenital heart disease other than mitral valve prolapse or a PFO\n10. Subject had coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) in the prior 6 months or is anticipated to undergo CABG or PCI within 12 months after randomization.\n11. Subject has any pacemaker with an intracardiac sensing or pacing lead or wire implanted in the prior 3 months, or CardioMEMS HF System or other intracardiac pressure monitoring system, or cardiac contractility modulation system or baroreceptor activation therapy implanted within the prior 3 months, or any plans to implant any of these devices within 12 months after the procedure.\n12. Subject has undergone atrial fibrillation ablation within the prior 6 months or is anticipated to undergo atrial fibrillation ablation within 12 months after randomization.\n13. Subject has undergone heart valve surgery or transcatheter valve intervention within the prior 6 months or is anticipated to undergo heart valve surgery or transcatheter valve intervention (e.g., valve repair or replacement, valvuloplasty) within 12 months after randomization.\n14. Subject has any tricuspid or pulmonic valve implants (implanted annuloplasty rings are allowed).\n15. Subject has an inferior vena cava (IVC) filter implant.\n16. Subject has received a prior heart or heart-lung transplantation or is listed for heart or heart-lung transplantation or is anticipated to receive a ventricular assist device (VAD) implant within 6 months after randomization.\n17. Subjects with intracardiac thrombus on TTE.\n18. Subjects with pericardial effusion ≥10 mm on TTE\n19. Subject's PH is predominantly due to WHO Group 1, 3, 4, or 5. Note: Multifactorial features of PH may be present, but the predominant diagnosis must be WHO Group 2 CpcPH.\n20. Subject has been treated with any group 1 PAH-targeted drugs, including sotatercept, within the prior month or is planned to receive such therapy after randomization.\n21. Subject is anticipated to undergo any surgery within 6 months after randomization (other than minor surgeries requiring only local anesthesia).\n22. Subject has severe renal insufficiency (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m2 by the CKD-EPI formula, or on dialysis).\n23. Subject has severe liver insufficiency (Child-Pugh classification C).\n24. Subject has platelet count \\\u003C100 × 109\u002FL.\n25. Subject has systemic inflammatory or other disease requiring long-term use of oral glucocorticoids or immunosuppressants.\n26. Subject has active infection requiring oral or intravenous antibiotics.\n27. Subject has a body mass index (BMI) \\>45 kg\u002Fm².\n28. Subjects with severe respiratory disease, defined as any disorder of the respiratory system with diffusing capacity of the lungs for carbon monoxide (DLCO) \\\u003C40% AND total lung capacity (TLC) \\\u003C60% AND forced expiratory volume in one second (FEV1) \\\u003C70% by plethysmography; OR who require ambulatory or long-term oxygen therapy\n29. Subject has known severe untreated sleep apnea. Note: Subjects with sleep apnea treated with CPAP\u002FBiPAP for at least the prior 3 months are not excluded.\n30. Subjects with pulmonary embolism or deep vein thrombosis in the prior 6 months.\n31. Subject is a pregnant or breastfeeding woman, or a woman planning to become pregnant within one year. Women of child-bearing potential must have a negative pregnancy test within 1 week of randomization.\n32. Subject is participating in another clinical trial of an investigational drug or device that has not reached its primary endpoint.\n33. Subject has severe cachexia\u002Ffrailty, substance abuse, or any other condition that the investigator believes may affect the subject's ability to comply with or complete all the study requirements including follow-up visits.\n34. Subject is a member of a vulnerable population who, in the judgment of the investigator, is unable to give Informed Consent for reasons of incapacity, immaturity, adverse personal circumstances or lack of autonomy. This may include individuals with mental disability, children, impoverished persons, persons in prisons, persons in emergency situations, homeless persons, nomads, refugees, and those incapable of giving informed consent. Vulnerable populations may also include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces, and persons kept in detention.","85 Years",{"count":67,"type":21},750,[24],"The goal of this clinical study is to evaluate the safety and efficacy of percutaneous pulmonary artery denervation with the Multi-Pole Pulmonary Artery Radiofrequency Ablation Enhancor System in patients with combined pre- and post-capillary pulmonary hypertension (CpcPH) associated with left heart disease (LHD). This randomized control trial will compare the investigational device (The Enhancor System) to control (medical therapy.)\n\nParticipants who will consist of patients with chronic heart failure (HF) who are receiving maximally tolerated guideline-directed medical therapy (GDMT) for left heart failure, are clinically stable, and who have been diagnosed with CpcPH by right heart catheterization (RHC), will be treated with PADN and followed for 3 years.",[71,72,73,74,75,27,28,29],"Pulmonary Hypertension","Heart Failure With Reduced Ejection Fraction","Hypertension","Vascular Diseases","Cardiovascular Diseases",[77,78,27,79,80],"Pulmonary Artery Denervation","Pulmonary Hypertension Due to Left Heart Disease","pulmonary hypertension","left heart failure","NOT_YET_RECRUITING","2026-03-11",{"date":84,"type":48},"2026-03-12",{"date":86,"type":21},"2026-04-01",{"date":88,"type":21},"2031-12-31",{"name":90,"class":55},"Pulnovo Medical, Inc.",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":99,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":100,"targetDuration":102,"studyType":103,"phases":4,"briefSummary":104,"conditions":105,"keywords":109,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":126},"100322647","biomechanical-precision-medicine-registry-for-patients-with-and-without-heart-failure-100322647","NCT03480633","Biomechanical Precision Medicine Registry for Patients With and Without Heart Failure","Preserved vs. Reduced Ejection Fraction Biomarker Registry and Precision Medicine Database for Ambulatory Heart Failure Patients (PREFER-HF) Study","PREFER-HF","Inclusion criteria for patients with HF:\n\n* 18 years and older\n* History of clinical symptoms consistent with HF and at least one of the following supporting evidence of HF:\n\n  * NT-proBNP \\> 125 pg\u002FmL\n  * BNP \\> 35 pg\u002FmL\n  * Capillary wedge pressure ≥ 15 mmHg on right heart catheterization or CI \\\u003C2.8 L\u002Fmin\u002Fm2\n  * LVEDP ≥ 15 mmHg\n  * Radiographic evidence of pulmonary edema\n  * Improvement in symptoms with diuretic initiation of increase\n  * CPET evidence of cardiac etiology of symptoms\n\nHFpEF: LVEF ≥ 50% HFrEF: LVEF \\\u003C50%\n\nExclusion criteria (for all patients, including both those with HFpEF and HFrEF):\n\n\\- End stage renal disease on dialysis",true,{"count":101,"type":21},3000,"50 Months","OBSERVATIONAL","In this single-center, longitudinal observational study, we will comprehensively examine clinical characteristics, proteomic, metabolomic, genomic and imaging data to better understand how different heart failure types may develop and progress over time. We will evaluate distinct sub-groups of heart failure (also known as heart failure phenotypes) and cardiomyopathies including amyloidosis with an ultimate goal of bringing the right medications and therapy to the right patients to optimize benefit and minimized side effects, an effort to improve precision medicine in heart failure.",[106,72,107,29,108],"Heart Failure With Normal Ejection Fraction","Heart Failure, Right Sided","Cardiovascular Risk Factor",[34,110,111,112,113,114,115],"Precision medicine","High risk patients","Pathophysiology","Bioregistry","Biomarkers","Heart failure etiology","2025-12-02",{"date":118,"type":48},"2025-12-09",{"date":120,"type":48},"2016-04-07",{"date":122,"type":21},"2027-10-06",{"name":124,"class":125},"Massachusetts General Hospital","OTHER",1,{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":134,"targetDuration":136,"studyType":103,"phases":4,"briefSummary":137,"conditions":138,"keywords":139,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":126},"100555782","demographic-clinical-biological-treatment-characteristics-and-cardiovascular-events-of-patients-with-heart-failure-in-vietnam-a-multicenter-prospective-observational-study-100555782","NCT06516562","Demographic, Clinical, Biological, Treatment Characteristics and Cardiovascular Events of Patients With Heart Failure in Vietnam: a Multicenter Prospective Observational Study","MCR-HF","Inclusion Criteria:\n\n* Patients aged 18 years and older\n* Diagnosed with heart failure at the time of discharge\n* Have an ejection fraction (based on imaging modalities such as echocardiography or cardiac MRI) recorded closest to the time of discharge, showing a left ventricular ejection fraction of less than 50%\n\nExclusion Criteria:\n\n* Patients and their relatives do not have means of communication with healthcare staff (phone, computer, messaging, etc.)\n* Patients do not reside in Vietnam after discharge",{"count":135,"type":21},2500,"12 Months","Describe the clinical characteristics, paraclinical features, and treatment during hospitalization, as well as at 1, 3, and 12 months post-discharge, of heart failure patients at selected cardiovascular centers in Vietnam.",[27,72,29],[140,34,141,142,143,144,145],"Patient registry","Prospective Observational Study","Demographic","Treatment characteristics","Prognosis","MACE","2024-12-03",{"date":148,"type":48},"2024-12-06",{"date":150,"type":48},"2023-08-01",{"date":152,"type":21},"2028-06-01",{"name":154,"class":125},"University Medical Center Ho Chi Minh City (UMC)",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":163,"enrollmentInfo":164,"targetDuration":4,"studyType":22,"phases":166,"briefSummary":168,"conditions":169,"keywords":170,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":126},"100502643","phase-3-a-trial-to-evaluate-the-safety-and-efficacy-of-pulmonary-artery-denervation-for-the-treatment-of-pulmonary-hypertension-associated-with-left-heart-failure-100502643","NCT05824923","A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension Associated With Left Heart Failure","A Prospective, Multicenter, Randomized Controlled Trial to Evaluate the Safety and Efficacy of Single-use Ring-shaped Pulmonary Artery Radiofrequency (RF) Ablation Catheter and Pulmonary Artery RF Ablation Generator for the Treatment of Pulmonary Hypertension Associated With Left Heart Failure","PADN-HF-PH","Inclusion Criteria:\n\n1. Age ≥18, ≤75 years old;\n2. Diagnosed with chronic heart failure for at least 3 months, and have received the GDMT pharmacological treatment based on the 2023 ESC Guidelines for Heart Failure for at least 1 month;\n3. Clinically stable defined by\n\n   1. No intravenous diuretics, inotropes or vasodilators for at least 1 month, and\n   2. Systolic blood pressure (SBP) ≥ 100 and \\\u003C 160 mmHg and resting heart rate (HR) ≥50 and \\\u003C100 bpm (\\\u003C110 bpm for atrial fibrillation) on the day of the procedure\n4. New York Heart Association (NYHA) class II-IVa;\n5. 6MWD ≥ 100 m and \\\u003C 450 m;\n6. NT-proBNP \\> 125 pg\u002FmL (BNP \\> 35 pg\u002FmL);\n7. Hemodynamic indicators (RHC) :\n\n   1. Mean pulmonary arterial pressure (mPAP) \\> 20 mmHg\n   2. Pulmonary capillary wedge pressure (PCWP) \\>15 mmHg\n8. Understand and be willing to sign informed consent, and be willing to follow the follow-up plan required by the protocol.\n\nExclusion Criteria:\n\n1. Any of the following:\n\n   1. Hypertrophic cardiomyopathy with left ventricular outflow tract obstruction or systolic anterior motion; pericardial disease; infiltrative or inflammatory myocardial disease; valvular stenosis of any of the 4 valves, or severe regurgitation of aortic and pulmonary valves, or active endocarditis; or\n   2. Symptomatic carotid stenosis, or transient ischemic attack (TIA) or stroke within 30 days prior to randomization; or\n   3. Untreated congenital heart disease; or\n   4. Have received any revascularization, including coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) within 6 months prior to randomization; or anticipated to undergo coronary revascularization (CABG or PCI) within 6 months; or\n   5. Artificial pacemakers, including single-chamber, dual-chamber and three-chamber pacemakers, have been implanted or are anticipated to be implanted within 6 months; or\n   6. Anticipated to undergo ablation of atrial fibrillation within 6 months; or\n   7. Anticipated to undergo heart valve surgery (valve replacement, valvuloplasty) within 6 months; or\n   8. Listing for heart\u002Fheart-lung transplantation or anticipated to implant a ventricular assist device (VAD)\n2. Other types of pulmonary hypertension, including WHO Group1, Group3, Group4, Group5;\n3. Received pulmonary arterial hypertension (PAH) targeted drugs within 1 month prior to randomization;\n4. Anticipated to undergo any surgery within 6 months;\n5. The cardiac index (CI) of RHC \\\u003C 1.5L\u002Fmin\u002Fm²;\n6. Severe renal insufficiency (eGFR \\\u003C30mL\u002Fmin\u002F1.73m² by MDRD formula);\n7. Severe liver insufficiency (Child-Pugh classification C);\n8. Platelet count \\\u003C 50 × 10\\^9\u002FL;\n9. Life expectancy \\\u003C1 year;\n10. Systemic inflammation or other disease requiring long-term use of glucocorticoids or immunosuppressants;\n11. Active infection requiring oral or intravenous antibiotics;\n12. Body mass index (BMI) \\>40 kg\u002Fm²;\n13. Pregnant or lactating women, or plan to pregnant in one year;\n14. Participated in other clinical trials within 3 months prior to signing the informed consent;\n15. Any other circumstances that investigators deem inappropriate to participate in this trial.","75 Years",{"count":165,"type":21},264,[167],"PHASE3","It's a phase III, prospective, multicenter, randomized controlled trial to evaluate the safety and efficacy of the pulmonary artery denervation (PADN) for heart failure (HF) patients diagnosed with pulmonary hypertension associate with left heart disease (PH-LHD) by right heart catheterization.",[71,72,73,74,75,27,28,29],[77,78,27,79,80],"2024-09-18",{"date":173,"type":48},"2024-09-20",{"date":175,"type":48},"2023-08-14",{"date":177,"type":21},"2027-02",{"name":179,"class":55},"Pulnovo Medical (Wuxi) Co., Ltd."]